Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Giltiay, Natalia V.
Shu, Geraldine L.
Clark, Edward A.
Funding for this research was provided by:
UCB Pharma (Unrestricted Research Grant)
National Institute of Allergy and Infectious Diseases (AI44257)
Text and Data Mining valid from 2017-05-15
Version of Record valid from 2017-05-15
18 October 2016
24 March 2017
15 May 2017